Trials / Not Yet Recruiting
Not Yet RecruitingNCT07377838
Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of ADSTEM Inj. for Moderate to Severe Subacute and Chronic Atopic Dermatitis Patients
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 286 (estimated)
- Sponsor
- EHL Bio Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Study of ADSTEM Injection for Patients with Moderate to Severe Subacute and Chronic Atopic Dermatitis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ADSTEM Inj. | hAD-MSC 1.0x10\^8 cells |
| DRUG | Placebo | 0.9% Normal Saline Inj. |
Timeline
- Start date
- 2026-06-01
- Primary completion
- 2029-06-01
- Completion
- 2029-12-01
- First posted
- 2026-01-30
- Last updated
- 2026-02-12
Source: ClinicalTrials.gov record NCT07377838. Inclusion in this directory is not an endorsement.